Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01F: MK-1084 in Previously Treated Advanced or Metastatic Nonsquamous NSCLC With KRAS G12C Mutations
NCT07286149Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of calderasib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Apr 2026; status: recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07286149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286149.